Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-15
2010-06-15
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S302000
Reexamination Certificate
active
07737160
ABSTRACT:
Compounds having the formulaare useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
REFERENCES:
patent: 3470183 (1969-09-01), Roth et al.
patent: 4767766 (1988-08-01), Baker et al.
patent: 5434150 (1995-07-01), Austel et al.
patent: 5834500 (1998-11-01), Wagner et al.
patent: 2001/0044538 (2001-11-01), Cheng et al.
patent: 2002/0004511 (2002-01-01), Luzzio et al.
patent: 2002/0013354 (2002-01-01), Cheng et al.
patent: 2002/0151544 (2002-10-01), Hayakawa et al.
patent: 2005/0143398 (2005-06-01), Das et al.
patent: 2006/0069116 (2006-03-01), Ashton et al.
patent: 2006/0100232 (2006-05-01), Summers et al.
patent: 2007/0032512 (2007-02-01), Ji et al.
patent: 2007/0093515 (2007-04-01), Arrington et al.
patent: 2008/0021026 (2008-01-01), Kahraman et al.
patent: 0438261 (1991-07-01), None
patent: 97-13771 (1997-04-01), None
patent: 98-47879 (1998-10-01), None
patent: 00-39108 (2000-06-01), None
patent: 01-19828 (2001-03-01), None
patent: 02-071827 (2002-09-01), None
patent: 03/000688 (2003-01-01), None
patent: 03-000688 (2003-01-01), None
patent: 03-022852 (2003-03-01), None
patent: 03-059354 (2003-07-01), None
patent: 2004/100947 (2004-11-01), None
patent: 2004-100947 (2004-11-01), None
patent: 2006-030031 (2006-03-01), None
patent: 2007-054831 (2007-05-01), None
patent: 2007-056625 (2007-05-01), None
Abdelraek et al., “Synthesis of novel thieno[2,3-d]pyrimidine, theino[2,3-b]pyridine and thiazolo[3,2-a]pyrimidine derivatives and their effect on the production of mycotoxins”, Arch. Pharm. (Weinheim) 325:301-305 (1992).
Abdelrazek et al., “Heterocyclic synthesis with nitriles: a new approach to thiophene and thieno[2,3-d]-pyrimidine derivatives”, Journal F. Prakt. Chemie Band 330(4):585-589 (1988).
Abdelrazek et al., “Heterocyclic synthesis with nitriles: a novel synthesis of some thiophene and thieno[2,3-d] pyrimidine derivatives, II [1]”, Z. Naturforsch, B.: Chemical Sci. 44(4):488-492 (1989).
Abdelrazek et al., “Heterocyclic synthesis with nitriles: synthesis of some new thiophene and thieno[2,3-d]pyrimidine derivatives IV”, Phosphorous, Sulfur, and Silicon 1:271-277 (1996).
Abdelrazek et al., “Heterocyclic synthesis with nitriles: synthesis of some novel thiophene and thieno[2,3-d]pyrimidine derivatives”, Phosphorous, Sulfur, and Silicon 71:93-97 (1992).
Dave et al., “Gold-Jacob type of reaction in the synthesis of thieno[3,2-e]pyrimido{1,2-c}pyrimidines: a comparison of classical heating vs. solvent-free microwave irradiation”, Heterocycles 51(8):1819-1826 (1999).
Ferrera et al., “The biology of VEGF and its receptors”, Nature Medicine 9(6):669-676 (2003).
Heyman et al., “Thienopyridine urea inhibitors of KDR kinase”, Bioorganic & Medicinal Chemistry Letters 17 (5):1246-1249 (2007).
Kandeel et al., “Nitriles in heterocyclic synthesis: a novel synthesis of some thieno[2,3-d]pyrimidine and thieno[2,3-b] pyridine derivatives”, Heteroatom Chemistry 7(1);29-33 (1996).
Nelson et al., “Dicyclic and Tricyclic Diaminopyrimidine derivatives as potent inhibitors of cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations”, Antimicrobial Agents and Chemotherapy 45(12):3293-3303 (2001).
Rosowsky et al. “2,4-diaminothieno[2,3-d]pyrimidines as antifolates and antimalarials. 3. Synthesis of 5,6-disubstituted derivatives and related teatracylic analogs”, J. Med. Chem. 16(3):191-194 (1973).
Roth et al., “2,4-diaminopyrimidines. The cyclization of 6-phenacylthio and related derivatives to thieno[2,3-d] pyrimidines and thiazolo[3,2-c]pyrimidines”, J. Med. Chem. 12(2):227-232 (1969).
Sherif et al., “Synthesis with heterocyclic beta-enaminonitriles: an expeditious synthetic approach to polyfunctionally substituted 5-phenyl-sulfonylthiophenes and their fused derivatives”, Monatshefte fur Chemis 128:687-696 (1997).
Taylor et al., “Synthesis of thieno[2,3-d]pyrimidine analogues of the potent antitumor agent N-{4-[2-[(2-amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]-benzoyl}-1-glutamic acid (LY231514)”, Heterocycles 43(2):349-365 (1996).
Underiner et al., “Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy”, Curr. Med. Chem. 11:731-745 (2004).
Co-pending U.S. Appl. No. 12/623,026.
Co-pending U.S. Appl. No. 12/632,183.
Betschmann Patrick
Burchat Andrew F.
Calderwood David J.
Curtin Michael L.
Davidsen Steven K.
Abbott Laboratories Inc.
Rahmani Niloofar
Seaman D. Margaret
Steele Susan L.
LandOfFree
Thienopyridine and furopyridine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienopyridine and furopyridine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienopyridine and furopyridine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4243750